Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Abstract

Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between… (More)
DOI: 10.3906/sag-1611-97

2 Figures and Tables

Topics

  • Presentations referencing similar topics